Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Common Equity (2020 - 2025)

Historic Common Equity for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $431.9 million.

  • Maravai Lifesciences Holdings' Common Equity fell 2951.53% to $431.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.9 million, marking a year-over-year decrease of 2951.53%. This contributed to the annual value of $577.2 million for FY2024, which is 2692.48% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Common Equity of $431.9 million as of Q3 2025, which was down 2951.53% from $468.0 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Common Equity registered a high of $905.2 million during Q4 2022, and its lowest value of $209.8 million during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $654.3 million (2022), whereas its average is $650.9 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Common Equity soared by 25242.33% in 2021 and then plummeted by 3941.86% in 2025.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Common Equity stood at $545.4 million in 2021, then surged by 65.99% to $905.2 million in 2022, then dropped by 12.74% to $789.9 million in 2023, then decreased by 26.92% to $577.2 million in 2024, then decreased by 25.18% to $431.9 million in 2025.
  • Its Common Equity stands at $431.9 million for Q3 2025, versus $468.0 million for Q2 2025 and $530.3 million for Q1 2025.